Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Policy / Regulatory

Shanghai to Launch China’s Largest ADR Database, Enhancing Pharmaceutical Oversight

Fineline Cube Apr 4, 2007

Shanghai is advancing towards a significant milestone in pharmaceutical safety with plans to establish the...

Policy / Regulatory

China Unveils TCM Development Guidelines: A Strategic Defense of Traditional Medicine

Fineline Cube Apr 4, 2007

In a strategic move to assert the value and historical significance of Traditional Chinese Medicine...

Company

India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers

Fineline Cube Apr 4, 2007

In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against...

Company

Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006

Fineline Cube Apr 4, 2007

Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...

Hospital R&D

Ruijin Hospital Researchers Uncover Five New Mutations in Rare 17OHD Endocrine Disorder

Fineline Cube Apr 4, 2007

In a significant advancement in endocrine research, scientists within the Endocrine Department at Ruijin Hospital...

Policy / Regulatory

China’s SFDA Mandates Official Position Rotation to Boost Transparency

Fineline Cube Apr 4, 2007

China’s State Food and Drug Administration (SFDA) is poised to embrace a new era of...

Policy / Regulatory

Guangdong’s ‘Sunlight Purchase’ System Sparks Drug Pricing War and Uncovers Pricing Anomalies

Fineline Cube Apr 4, 2007

Since 2007, Guangdong province’s medical facilities have utilized an online procurement system known as “Sunlight...

Hospital R&D

Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study

Fineline Cube Apr 4, 2007

In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17...

Policy / Regulatory

SFDA Embraces Transparency: Regular Press Briefings and Personnel Rotations Announced

Fineline Cube Apr 4, 2007

China’s State Food and Drug Administration (SFDA) is gearing up for a transparency overhaul, with...

Company

China’s Western Pharmaceutical Exports Soar 23% in 2006, Led by Antibiotics

Fineline Cube Apr 4, 2007

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Drug Medical Device

Shanghai Roche Pharmaceuticals Launches Erlotinib for Advanced Non-Small Cell Lung Cancer in China

Fineline Cube Apr 4, 2007

Shanghai Roche Pharmaceuticals Ltd. made headlines in March with the launch of its lung cancer...

Posts pagination

1 … 597 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.